An important message from NCRVA regarding coronavirus (COVID-19).

COVID-19 & Your Appointment
Northern California Retina Vitreous Associates logo for print
  • Daly City: 650-994-2100
  • San Mateo: 650-340-0111
  • Mountain View: 650-963-3460
  • Monterey: 831-373-6280
  • East San Jose: 408-251-3500
  • West San Jose: 408-356-8818
Reset Text size:
Reset Text size:

Clinical Trials

Device Studies

Active Studies

PAGODA (Roche)

A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA.

PAVILION (Roche)

A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY.

PORTAL (Roche/Genentech)

A multicenter, open-label extension study to evaluate the long-term safety and tolerabilty of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.

Completed Studies

ARCHWAY (Roche/Genentech)

A phase 3, multicenter, randomized, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.

CLEAR (DigiSight)

A 3 month, phase 1 and 2 studies on THE CORRELATION OF PAXOS CHECKUP MOBILE APP TO STANDARD IN OFFICE VISUAL ASSESSMENT.

LADDER (Genentech)

A 20 month, phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.